Jason draws on his pharmaceutical industry experience in synthetic organic chemistry, polymorphism, bioprocesses, drug discovery, analytical chemistry and formulation science to advise clients in the life science industries with a particular emphasis on pharmaceutical research and development.
MapLight Therapeutics Closes Oversubscribed $372.5 Million Series D
July 28, 2025
Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company developing targeted, novel therapies for patients with central nervous system disorders, on its oversubscribed $372.5 million Series D financing.
Cooley advised the underwriters of Caris Life Sciences, a patient-centric, next-generation artificial intelligence techbio company and precision medicine pioneer, in connection with Caris’ $494 million initial public offering (IPO).
Nuvation Bio Announces up to $250 Million Nondilutive Financings From Sagard Healthcare Partners
February 18, 2025
Cooley advised Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, on its nondilutive financings of up to $250 million with Sagard Healthcare Partners.
Geron Corporation Announces up to $375 Million in Funding With Royalty Pharma and Pharmakon Advisors
November 7, 2024
Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors.
